Alendronate treatment in cats with persistent ionized hypercalcemia: A retrospective cohort study of 20 cases
Résumé
Background:Limited information is available concerning treatment of ionizedhypercalcemia in cats.Hypothesis/Objectives:Describe clinical findings in a cohort of cats with persistentionized hypercalcemia and evaluate long-term tolerance and efficacy of alendronatein these patients.Animals:Twenty cats with persistent ionized hypercalcemia of undetermined origin,presented for routine or referral consultation at the teaching hospital of Maisons-Alfort (France).Methods:Medical records were retrospectively reviewed. Cats were divided intoGroup 1 (cats that received alendronate as well as other treatments, n=11) andGroup 2 (cats that did not receive alendronate, n=9). Survival analysis (Kaplan-Meier method, log-rank test, and Cox proportional hazard models) was conducted tocompare time to selected outcomes.Results:Azotemia was present in 15 cats (75%). Alendronate treatment was adminis-tered and well tolerated during the entire follow-up period (median, 9.5 months;interquartile range [IQR], 6.3; 27) in all cats from Group 1, except in 1 cat that devel-oped severe hypophosphatemia, prompting treatment discontinuation. Univariateanalysis determined that alendronate treatment was significantly associated withshorter time to reach a 15% decrease in ionized calcium concentration (iCa) frombaseline during follow-up (119 days vs median not reached,P=.02). This associationwas no longer significant after adjustment for age and initial iCa.Conclusions and Clinical Importance:Alendronate overall was well tolerated withchronic use in this cohort, and can be considered a treatment option for persistentionized hypercalcemia in cats.
Origine : Fichiers éditeurs autorisés sur une archive ouverte